The earnings call highlighted significant achievements such as strong revenue growth, patent extension, and international expansion plans. However, there were challenges like increased expenses and expected choppy gross to net dynamics. Overall, the positive developments and strategic advancements outweigh the challenges faced.

Company Guidance

During the second quarter of 2025, Madrigal Pharmaceuticals provided guidance highlighting several key metrics and strategic initiatives. Rezdiffra, their leading product, achieved a quarterly run rate exceeding $200 million, with net sales totaling $212.8 million, marking a 55% increase from the previous quarter. The company reported over 23,000 patients actively on Rezdiffra, reflecting substantial growth from over 17,000 in the first quarter. Additionally, physician penetration reached 80% among their top 6,000 targets, with 60% penetration in their broader 14,000 target prescriber base. Madrigal also emphasized the impact of their newly issued U.S. patent, extending protection for Rezdiffra until February 2045, which is expected to significantly enhance its long-term value. Looking forward, the company is preparing for international expansion, starting with Germany, and exploring new therapeutic combinations, such as a promising oral GLP-1, to further solidify their leadership in the MASH market.

Strong Revenue Growth

Rezdiffra’s net sales reached $213 million, up 55% quarter-over-quarter, annualizing at over $800 million.

Significant Patent Extension

New U.S. patent for Rezdiffra extends protection to February 2045, providing a significant long-term strategic advantage.

High Prescriber Penetration

80% of top 6,000 targets have prescribed Rezdiffra, with significant progress in expanding to a broader base of 14,000 target prescribers.

International Expansion Plans

Preparations underway for Rezdiffra launch in Germany in the second half of this year, following a positive CHMP opinion.

Pipeline Expansion with Oral GLP-1

Secured SYH2086 oral GLP-1 asset for $120 million upfront, with plans to enter the clinic in the first half of next year.

Strong Cash Position

Ended the quarter with $802 million in cash and secured an additional $500 million credit facility with Blue Owl Capital.

Madrigal Pharmaceuticals (MDGL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MDGL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-1.95 / -	-4.92	―	―	―
Aug 05, 2025	2025 (Q2)	-3.55 / -1.90	-7.1	73.24% (+5.20)
May 01, 2025	2025 (Q1)	-3.75 / -3.32	-7.38	55.01% (+4.06)	―
Feb 26, 2025	2024 (Q4)	-3.92 / -2.71	-5.68	52.29% (+2.97)	―
Oct 31, 2024	2024 (Q3)	-6.75 / -4.92	-5.34	7.87% (+0.42)	―
Aug 07, 2024	2024 (Q2)	-7.54 / -7.10	-4.69	-51.39% (-2.41)	―
May 07, 2024	2024 (Q1)	-6.29 / -7.38	-4.23	-74.47% (-3.15)	―
Feb 28, 2024	2023 (Q4)	-5.24 / -5.68	-4.98	-14.06% (-0.70)	―	―
Nov 06, 2023	2023 (Q3)	-4.90 / -5.34	-4.75	-12.42% (-0.59)	―	―
Aug 08, 2023	2023 (Q2)	-4.59 / -4.69	-4.14	-13.29% (-0.55)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MDGL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$312.11	$338.91	+8.59%
May 01, 2025	$333.91	$327.70	-1.86%
Feb 26, 2025	$309.49	$355.88	+14.99%
Oct 31, 2024	$215.93	$259.34	+20.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Madrigal Pharmaceuticals Inc (MDGL) report earnings?

Madrigal Pharmaceuticals Inc (MDGL) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is Madrigal Pharmaceuticals Inc (MDGL) earnings time?

Madrigal Pharmaceuticals Inc (MDGL) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MDGL EPS forecast?

MDGL EPS forecast for the fiscal quarter 2025 (Q3) is -1.95.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing